Larimar Therapeutics
LRMR
163 hedge funds and large institutions have $293M invested in Larimar Therapeutics in 2026 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 68 increasing their positions, 41 reducing their positions, and 29 closing their positions.
66% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 41
14% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 29
7.4% more ownership
Funds ownership: 84.48% → 91.88% (+7.4%)
1% more funds holding
Funds holding: 162 → 163 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
26% less capital invested
Capital invested by funds: $395M → $293M (-$102M)
45% less call options, than puts
Call options by funds: $1.68M | Put options by funds: $3.05M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Defilade Capital Management
Emeryville,
California
|
+$14.6M |
| 2 |
BOCH
Blue Owl Capital Holdings
New York
|
+$8.11M |
| 3 |
BlackRock
New York
|
+$7.65M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$6.17M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$4.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$13.5M |
| 2 |
Millennium Management
New York
|
-$9.1M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$6.75M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.62M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$3.49M |
LRMR Hedge Fund Activity: Q2 2026 in Review
163 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q2 2026, worth a combined $293M — down 26% from $395M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new LRMR positions and 29 closed out — a net gain of 4 holders — while 68 added to existing stakes and 41 trimmed.
The largest buyer was Defilade Capital Management, opening a new position worth an estimated $14.6M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $13.5M sold.
- 163 institutional investors held Larimar Therapeutics (LRMR) as of Q2 2026, up from 162 in Q1 2026.
- Funds reported $293M of Larimar Therapeutics stock for Q2 2026, down 26% quarter-over-quarter.
- 33 funds opened new Larimar Therapeutics positions in Q2 2026 and 29 closed out, a net change of +4 holders.
- The largest Larimar Therapeutics buyer in Q2 2026 was Defilade Capital Management, an estimated $14.6M added.
- The largest Larimar Therapeutics seller in Q2 2026 was AIGH Capital Management, an estimated $13.5M sold.
Based on aggregated 13F filings for Q2 2026.